Product Description
Eribulin injection is used to treat metastatic (cancer that has already spread to other parts of the body) breast cancer in patients who have already received other types of cancer medicines. Eribulin injection is also used to treat metastatic liposarcoma or liposarcoma that cannot be removed with surgery in patients who have received other types of cancer medicines.
Mechanisms of Action: Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: Breast Cancer | Oncology Solid Tumor Unspecified | Oncology Unspecified
Known Adverse Events: Alopecia | Anemia | Neutropenia | Asthenia | Constipation
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, France, Germany, Greece, Israel, Italy, Japan, Korea, Poland, Spain, Switzerland, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 44
Highest Development Phases
Phase 3: Breast Cancer|Male Breast Cancer
Phase 2: Alopecia|Brain Cancer|Carcinosarcoma|Colorectal Cancer|Epithelioid Hemangioendothelioma|Esophageal Cancer|Gastrointestinal Cancer|Hemangiopericytoma|Hemangiosarcoma|Hepatocellular Carcinoma|Histiocytoma, Malignant Fibrous|Leiomyosarcoma|Liposarcoma|Melanoma|Mixed Tumor, Mullerian|Oncology Solid Tumor Unspecified|Pancreatic Cancer|Rhabdomyosarcoma|Sarcoma|Sarcoma, Ewing|Small Cell Lung Cancer|Solitary Fibrous Tumors|Triple Negative Breast Cancer
Phase 1: Adenoid Cystic Carcinoma|Adrenocortical Carcinoma|Endometrial Cancer|Esophageal Cyst|Healthy Volunteers|Lymphoma|Papillary Carcinoma|Peritoneal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Morpheus-panBC | P2 |
Recruiting |
Breast Cancer |
2028-05-03 |
|
| The ARETHA Study | P2 |
Recruiting |
Triple Negative Breast Cancer |
2027-10-01 |
|
| 02AB21-TucErBit | P2 |
Recruiting |
Breast Cancer |
2027-06-01 |
23% |
| E7386-J081-102 | P1 |
Recruiting |
Hepatocellular Carcinoma|Endometrial Cancer|Colorectal Cancer |
2027-03-15 |